Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02696902
Previous Study | Return to List | Next Study

Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects (EVADE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02696902
Recruitment Status : Completed
First Posted : March 2, 2016
Last Update Posted : December 20, 2019
Sponsor:
Collaborators:
INNOVATIVE MEDICINES INITIATIVE and COMBACTE-MAGNET
Antibacterial Resistance Leadership Group
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
MedImmune LLC

Brief Summary:
Clinical Trial looking to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas aeruginosa

Condition or disease Intervention/treatment Phase
Pseudomonas Aeruginosa Drug: MEDI3902 Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 188 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa
Actual Study Start Date : March 25, 2016
Actual Primary Completion Date : December 4, 2019
Actual Study Completion Date : December 4, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arm Intervention/treatment
Active Comparator: MEDI3902 Drug: MEDI3902
Active

Placebo Comparator: Placebo Other: Placebo
Placebo




Primary Outcome Measures :
  1. Safety of single intravenous (IV) doses of MEDI3902 as measured by adverse events and clinical laboratory parameters. [ Time Frame: 49 days post dose ]
    Safety of MEDI3902 as measured by adverse events and clinical laboratory parameters.

  2. Efficacy of single intravenous (IV) doses of MEDI3902 as measured by signs and symptoms of nosocomial pneumonia caused by P aeruginosa [ Time Frame: 21 days post dose ]
    Nosocomial pneumonia will be diagnosed using signs and symptoms, including a culture positive for P aeruginosa and X-ray positive for pneumonia


Secondary Outcome Measures :
  1. Single-dose pharmacokinetic (PK) parameters of MEDI3902 in serum. [ Time Frame: 49 days post dose ]
    Cmax

  2. Anti-drug Antibody (ADA) responses to MEDI3902 in serum [ Time Frame: 49 days post dose ]
    Incidence and titers of ADA to MEDI3902 in serum

  3. Single-dose pharmacokinetic (PK) parameters of MEDI3902 in serum. [ Time Frame: 49 days post dose ]
    Tmax

  4. Single-dose pharmacokinetic (PK) parameters of MEDI3902 in serum [ Time Frame: 49 days post dose ]
    t1/2

  5. Single-dose pharmacokinetic (PK) parameters of MEDI3902 in serum. [ Time Frame: 49 days post dose ]
    AUC



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Colonized with P aeruginosa, expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia.

Exclusion Criteria:

P aeruginosa disease at randomisation; lung injury score consistent with pneumonia; current lung disease; currently receiving protocol-specified Anti-P aeruginosa antibiotics, moribund patients.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02696902


Locations
Show Show 78 study locations
Sponsors and Collaborators
MedImmune LLC
INNOVATIVE MEDICINES INITIATIVE and COMBACTE-MAGNET
Antibacterial Resistance Leadership Group
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Study Director: MedImmune LLC MedImmune LLC
Layout table for additonal information
Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT02696902    
Other Study ID Numbers: D5470C00004
First Posted: March 2, 2016    Key Record Dates
Last Update Posted: December 20, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by MedImmune LLC:
Pseudomonas aeruginosa, Pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Pseudomonas Infections
Healthcare-Associated Pneumonia
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Cross Infection
Infection
Iatrogenic Disease
Disease Attributes
Pathologic Processes